The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Camrelizumab plus famitinib for advanced renal cell carcinoma or unresectable urothelial carcinoma: Updated results from a phase II trial.
 
Yuan-Yuan Qu
No Relationships to Disclose
 
Qing Zou
No Relationships to Disclose
 
Hongqian Guo
No Relationships to Disclose
 
Nianzeng Xing
No Relationships to Disclose
 
Zhongquan Sun
No Relationships to Disclose
 
Weiqing Han
No Relationships to Disclose
 
Hong Luo
No Relationships to Disclose
 
Shujie Xia
No Relationships to Disclose
 
Xuepei Zhang
No Relationships to Disclose
 
Chaohong He
No Relationships to Disclose
 
Hailiang Zhang
No Relationships to Disclose
 
Jinling Cai
Employment - Jiangsu Hengrui Medicine
 
Xiao Zhang
Employment - Jiangsu Hengrui Medicine
 
Quanren Wang
Employment - Jiangsu Hengrui Medicine
 
Dingwei Ye
No Relationships to Disclose